logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

As of the end of August, the net asset value per share of Harbour Digital (00913) was approximately HKD 0.724.

date
15/09/2025
avatar
GMT Eight
Harbour Digital (00913) announced that on August 31, 2025, the company's ordinary shares per share...
HARBOUR DIGITAL(00913) announced that as of August 31, 2025, the unaudited net asset value per ordinary share of the company is approximately 0.724 Hong Kong dollars.
Related Articles
China Stock
Wuhan Tianyuan Group (301127.SZ) shareholder Konka Group terminates the public solicitation for the transfer of company shares.
HK Stock
XD INC (02400) issued a total of 70,300 shares due to the exercise of stock options.
HK Stock
CSPC PHARMA (01093): ALMB-0166 has received clinical trial approval in China for the treatment of Parkinson's disease.
Wuhan Tianyuan Group (301127.SZ) shareholder Konka Group terminates the public solicitation for the transfer of company shares.
China Stock
XD INC (02400) issued a total of 70,300 shares due to the exercise of stock options.
HK Stock
CSPC PHARMA (01093): ALMB-0166 has received clinical trial approval in China for the treatment of Parkinson's disease.
HK Stock
RECOMMEND
Hong Kong Stock Concept Tracker|Oracle (ORCL.US) RPO Surge Ignites AI Computing Power Chain—Domestic Opportunities in Focus
Hong Kong Stock Concept Tracker|Oracle (ORCL.US) RPO Surge Ignites AI Computing Power Chain—Domestic Opportunities in Focus
icon
11/09/2025
Southbound Capital Flows Shift: Profit-Taking on High-Flying Stocks and Accumulating Alibaba and Tence
Southbound Capital Flows Shift: Profit-Taking on High-Flying Stocks and Accumulating Alibaba and Tence
icon
11/09/2025
Anti-Involution Policies Deliver Results as August Price Indicators Improve
Anti-Involution Policies Deliver Results as August Price Indicators Improve
icon
11/09/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.